

Aseel Bin Sawad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/775270/publications.pdf>

Version: 2024-02-01

32
papers

58
citations

1937685

4
h-index

1588992

8
g-index

32
all docs

32
docs citations

32
times ranked

88
citing authors

#	ARTICLE	IF	CITATIONS
1	Natural history of arginase 1 deficiency and the unmet needs of patients: A systematic review of case reports. JIMD Reports, 2022, 63, 330-340.	1.5	6
2	Health care resource utilization in the management of patients with Arginase 1 Deficiency in the US: a retrospective, observational, claims database study. Journal of Medical Economics, 2022, 25, 848-856.	2.1	1
3	CO1 The Natural History, Clinical Outcomes and Unmet Needs of Patients with Arginase 1 Deficiency (ARG1-D): A Systematic Review of Case Reports. Value in Health, 2021, 24, S4.	0.3	0
4	PRO37 The Epidemiology, Methods of Diagnosis, and Clinical Management of Patients with Arginase 1 Deficiency (ARG1-D): A Systematic Review. Value in Health, 2021, 24, S204.	0.3	0
5	Response to Covid-19 Crisis: Recommendations and Health Policy Changes. International Journal of Pharma and Bio Sciences, 2021, 11, .	0.1	0
6	Fighting Covid-19 Pandemic: Analysis of the Swedish Model vs. Lockdown Model. International Journal of Pharma and Bio Sciences, 2021, 11, .	0.1	1
7	Treatment of Unruptured Cerebral Artery Aneurysm: A Meta-Analysis. International Journal of Pharma and Bio Sciences, 2021, 11, .	0.1	0
8	Clinical Trials of Solid Tumor Drugs Approved in Europe: Evidence-Based-Medicine. International Journal of Pharma and Bio Sciences, 2021, 11, .	0.1	0
9	PNS51 HEALTHCARE RESOURCE INDICATORS: THE WORLDWIDE TOP 3 COUNTRIES WITH THE MOST PHYSICIANS PER CAPITA VS. SAUDI ARABIA.. Value in Health, 2020, 23, S293.	0.3	0
10	ND3 ORPHAN DRUG MARKET ACCESS CHALLENGES IN EUROPEAN UNION FIVE.. Value in Health, 2020, 23, S9.	0.3	0
11	PND67 COMPARISON OF MULTIPLE SCLEROSIS DRUG PRICES IN SAUDI ARABIA VS. UNITED ARAB OF EMIRATES.. Value in Health, 2020, 23, S271.	0.3	0
12	Pharmaceutical pricing benchmarks: governmental versus private sector. Journal of Comparative Effectiveness Research, 2020, 9, 1091-1100.	1.4	1
13	Treatment of venous leg ulcers using bilayered living cellular construct. Journal of Comparative Effectiveness Research, 2020, 9, 907-918.	1.4	1
14	Price Analysis of Immunosuppressants Which are Approved By FDA as Anti-Rejection Therapy for Kidney Transplantation in the United States. Value in Health, 2018, 21, S266.	0.3	0
15	Systematic Assessment of Decision Analytic Models for the Cost Effectiveness of Immunosuppressive Agents Used In Kidney Transplant Patients. Value in Health, 2018, 21, S267.	0.3	0
16	Costâ€ effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis. Journal of Comparative Effectiveness Research, 2017, 6, 97-108.	1.4	10
17	Comparing the Expanded Disability Status Scale Versus the Multiple Sclerosis Functional Composite As Clinical Endpoints in Multiple Sclerosis Clinical Trials: A Quantitative Meta-Analysis. Value in Health, 2016, 19, A73.	0.3	0
18	Pivotal Studies of Oncology Drugs Approved in Europe, Which Evidence Based-Medicine?. Value in Health, 2016, 19, A717.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Overall Survival Versus Progression-Free Survival in Oncology Clinical Trials. Value in Health, 2016, 19, A717.	0.3	1
20	Continental Comparison of Innovative Drugs Prices, The Case of Oncology Used for Treatment of Solid Tumors in Germany and The United States. Value in Health, 2016, 19, A758.	0.3	0
21	Market Access And Pricing Disparities of Anticancer Drugs Marketed In The Oecd Countries: Which Reality?. Value in Health, 2016, 19, A4.	0.3	0
22	Oncology Drugs Lag Between Europe and other Countries: Comparaison between EMA and others Agencies (FDA, Health Canada, TGA, and Swissmedic). Value in Health, 2016, 19, A164-A165.	0.3	3
23	Approval of Oncology Drugs at World-Wide Level: An Independent or Linked Market?. Value in Health, 2016, 19, A164.	0.3	0
24	Price Analysis of Multiple Sclerosis Disease-Modifying Drugs: Comparison Between Saudi Arabia and the United States. Value in Health, 2016, 19, A62.	0.3	0
25	Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States. Current Medical Research and Opinion, 2016, 32, 1783-1788.	1.9	13
26	Cost-Effectiveness of Different Strategies for Treatment of Relapsing-Remitting Multiple Sclerosis. Value in Health, 2016, 19, A62.	0.3	0
27	Evaluation of the Expanded Disability Status Scale and the Multiple Sclerosis Functional Composite as clinical endpoints in multiple sclerosis clinical trials: quantitative meta-analyses. Current Medical Research and Opinion, 2016, 32, 1969-1974.	1.9	21
28	Price Analysis of Multiple Sclerosis Disease-Modifying Therapies Marketed in the US. Value in Health, 2015, 18, A282.	0.3	0
29	Analysis Of Average Manufacturer Prices Of New Drugs Approved In The United States (1990-2012). Value in Health, 2014, 17, A18-A19.	0.3	0
30	Analysis Of The Waxman-Hatch Act Pharmaceutical Patent Extensions (1984â€“2012). Value in Health, 2013, 16, A245.	0.3	0
31	COVID-19 Crisis: What is the Role of Telehealth?. Journal of Pharmaceutical Research International, 0, , 99-109.	1.0	0
32	Roles and Rules of Some Regulatory Agencies around the World during COVID-19 Pandemic. Journal of Pharmaceutical Research International, 0, , 178-187.	1.0	0